- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03815578
Evaluation of Pain Sensitization in Rheumatoid Arthritis: Analysis on a Cohort of Tofacitinib Treated Patients (TOPRA)
Persistent pain and chronic fatigue are very common complaints in rheumatoid arthritis (RA) patients, whatever the anti-inflammatory treatment response. Interestingly, pain remaining despite good clinical response was associated with high disability and low inflammation at baseline, suggesting a mechanism of pain independent of inflammation in these patients. Such patients, with discordantly high patient-reported DAS28 components, fatigue and mood disturbance might represent a subgroup of RA patients who have specific clinical needs, not resolved by classical conventional or biologic DMARDs. In this way, neuropathic pain and pain sensitization have been demonstrated in 20 to 30% of RA patients, neuropathic pain scores being associated with worsen disease activity scores. Thus, pain sensitization may contribute to amplification of pain in active RA, and should be responsible for persisting pain and fatigue even after inflammation has resolved.
Pain sensitization is associated with neuroplastic changes in sensory pathways at peripheral and central levels. Interestingly, major mediators responsible for this neuroplasticity operate via a JAK/STAT signaling pathway, which is specifically targeted by new RA treatments. New drug targeting JAK/STAT signalling pathway have been recently designed for RA treatment, based on the implication of this pathway on the signaling of various cytokines implicated in the pathophysiology of RA, such as IL-6, IL-12, IL-23 and IFNs. Two Jak-inhibitors have been put on the market: Tofacitinib and Baricitinib. In randomized clinical trials, Tofacitinib have shown a remarkable efficacy on pain and other patient reported outcomes, suggesting a specific effect or jak-inhibitors on pain control. Recent data suggest that Jak-inhibitors could have a direct effect on sensory neurons.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Thomas BARNETCHE, PhD
- Email: thomas.barnetche@chu-bordeaux.fr
Study Contact Backup
- Name: Thierry SCHAEVERBEKE, Prof
- Phone Number: +33 (0)556795556
- Email: thierry.schaeverbeke@chu-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France
- CHU de Bordeaux - service de rhumatologie
-
Limoges, France
- CHU de Limoges - service de rhumatologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged over 18 year-old ;
- Diagnosis of RA according to the ACR/EULAR 2010 classification criteria ;
- Active rheumatoid arthritis defined by a Disease Activity Score (DAS28) > 3.2 at inclusion ;
- Patient eligible for tofacitinib treatment in agreement with European treatment labelling and French recommendation for RA treatment ;
- Oral prednisone intake is allowed until 10 mg, stable for at least 1 week at study entry ;
- Starting tofacitinib treatment for an active RA defined by a DAS28-ESR > 3.2 ;
- Affiliated person or beneficiary of a social security scheme ;
- Having signed an informed consent (at the latest on the day of inclusion and before any examination required by research).
Exclusion Criteria:
- Diagnosis of a systemic autoimmune disease other than RA ;
- Peripheral neuropathy ;
- Centrally-acting pain medications use within 3 months of enrolment (amitriptyline, gabapentin, duloxetine), or during the study ;
- Any opioid use within 1 month of enrolment or during the study ;
- Corticosteroid treatment over 10 mg of prednisone or equivalent ;
- Patient who present contraindications to tofacitinib treatment ;
- Patient presenting with a history of active tuberculosis or chronic infectious disease with a need of regular use of antibiotic ;
- Patients with active bacterial or viral infection, or presenting with an episode of infection that required treatment with antibiotics within 30 days prior to screening ;
- Patient presenting with a history of lymphoma or leukaemia or other malignancy besides non-melanoma skin cancer within 5 years ;
- Patient presenting with any uncontrolled medical condition ;
- Pregnancy or breast-feeding ;
- Patient unable to understand and follow recommendations or unable to perform self-evaluation ;
- Patient who refuse to participate to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rheumatoid Arthritis (RA) patients
RA according to the ACR/EULAR 2010 classification criteria
|
18 ml whole blood for ELISA analysis and miRNAs detection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variation of the mean Pressure Pain Thresholds (PPTs)
Time Frame: At 6 months from baseline
|
At 6 months from baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Variation of Mechanical Temporal Summation (MTS)
Time Frame: At 1, 3 and 6 months from baseline
|
At 1, 3 and 6 months from baseline
|
|
Variation of Pressure Pain Thresholds (PPTs)
Time Frame: At 1, 3 and 6 months from baseline
|
At 1, 3 and 6 months from baseline
|
|
Variation of Diffuse noxious inhibitory control (DNIC) values
Time Frame: At 1, 3 and 6 months from baseline
|
At 1, 3 and 6 months from baseline
|
|
Variation of Daily joint pain intensity
Time Frame: At 1, 3 and 6 months from baseline
|
daily evaluation of the previous 24h pain on a numeric pain scale 0 to 100
|
At 1, 3 and 6 months from baseline
|
Disease activity evaluated by the Disease Activity Score on 28 joints (DAS28)
Time Frame: At 1, 3 and 6 months from baseline
|
which take into account the number of painful joints (on 28 joints), the number of swollen joints (on 28 joints), the patient global assessment of disease activity (between 0 and 100), and the erythrocyte sedimentation rate.
|
At 1, 3 and 6 months from baseline
|
Disease activity evaluated by the Simple Disease Activity Index (SDAI)
Time Frame: At 1, 3 and 6 months from baseline
|
which take into account the number of painful joints (on 28 joints), the number of swollen joints (on 28 joints), the patient global assessment of disease activity (between 0 and 100), the physician global assessment of disease activity (between 0 and 100), and the C-reactive protein level.
|
At 1, 3 and 6 months from baseline
|
Disease activity evaluated by the Clinical Disease Activity Index (SDAI)
Time Frame: At 1, 3 and 6 months from baseline
|
which take into account the number of painful joints (on 28 joints), the number of swollen joints (on 28 joints), the patient global assessment of disease activity (between 0 and 100), and the physician global assessment of disease activity (between 0 and 100).
|
At 1, 3 and 6 months from baseline
|
Health Assessment Questionnaire (HAQ)
Time Frame: At 1, 3 and 6 months from baseline
|
At 1, 3 and 6 months from baseline
|
|
Rheumatoid Arthritis Impact of Disease score (RAID)
Time Frame: At 1, 3 and 6 months from baseline
|
At 1, 3 and 6 months from baseline
|
|
Hospital Anxiety and Depression scale
Time Frame: At 1, 3 and 6 months from baseline
|
HAD scale aims at evaluating anxiety and depression symptoms with two separate scores (between 0 and 21) estimated grace to 14 items (7 for anxiety and 7 for depression) ranged between 0 and 3
|
At 1, 3 and 6 months from baseline
|
Coping Strategy Questionnaire: a 21-items self-report
Time Frame: At 1, 3 and 6 months from baseline
|
At 1, 3 and 6 months from baseline
|
|
Levels of cytokines
Time Frame: At 3 and 6 months from baseline
|
At 3 and 6 months from baseline
|
|
Levels of neurotrophins
Time Frame: At 3 and 6 months from baseline
|
At 3 and 6 months from baseline
|
|
Levels of miR21, miR-124, miR-146a and miR-155
Time Frame: At 3 and 6 months from baseline
|
At 3 and 6 months from baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Thierry SCHAEVERBEKE, Prof, CHU Bordeaux
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2017/39
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Clinical examination
-
University Hospital, Basel, SwitzerlandDePuy SynthesRecruitingArthroscopic Rotator Cuff Repair (ARCR)Switzerland
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruiting
-
Cukurova UniversityCompletedSurvival, Prosthesis | Clinical Acceptability, ProsthesisTurkey
-
Bezmialem Vakif UniversityThe Scientific and Technological Research Council of Turkey; Abant Izzet Baysal... and other collaboratorsCompleted
-
University Hospital, AkershusCompletedCongenital Heart DiseaseNorway
-
Cairo UniversityUnknown
-
CHU de ReimsCompletedErosive Pustular Dermatosis of the LegFrance
-
St. Olavs HospitalNational Taiwan Normal UniversityRecruiting
-
AspetarUniversity College DublinCompletedHip Pain Chronic | Inguinal Hernia | Groin Injury | Iliopsoas Syndrome | Adductor TendinitisQatar